Dr Arechavala-Gomeza (@VArechavala) studied Pharmacy in the University of the Basque Country, Spain, and an MSc in Immunopharmacology at the University of Strathclyde in Glasgow, Scotland.
During her PhD with Prof. Chris Shaw (Neurology, King’s College London) she studied SOD1 mutations that cause amyotrophic lateral sclerosis (ALS). Shortly after her PhD, she joined the laboratory of Prof. Francesco Muntoni as a postdoctoral researcher where she coordinated the preclinical development and the laboratory analysis of the two first proof of principle clinical trials of eteplirsen for the treatment of Duchenne muscular dystrophy.
In June 2013 Dr Arechavala-Gomeza joined the Biocruces Bizkaia Health Research Institute in Spain, where she leads a newly created Neuromuscular Disorders Research Group. She is particularly interested in the development of accurate biochemical outcome measures and in particular in dystrophin quantification, a field in which she has several publications.
She participates in several research networks: she is a founding member of SRUK/CERU (Spanish Researchers in the United Kingdom), and a member of CRE (Científicos retornados a España). She also collaborates with the TREAT-NMD neuromuscular network, was part of the management commitee of COST Action BM1207 , and she now leads a new COST Action on the delivery of antisense oligonucleotides (CA17103).